发布求助
文献互助 智能选刊 最新文献

Drug discovery today. Disease mechanisms最新文献

筛选
英文 中文
TSLP: a key regulator of asthma pathogenesis TSLP:哮喘发病机制的关键调节因子
Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 Epub Date: 2012-10-18 DOI: 10.1016/j.ddmec.2012.09.003
Erin E. West, Mohit Kashyap, Warren J. Leonard
{"title":"TSLP: a key regulator of asthma pathogenesis","authors":"Erin E. West,&nbsp;Mohit Kashyap,&nbsp;Warren J. Leonard","doi":"10.1016/j.ddmec.2012.09.003","DOIUrl":"10.1016/j.ddmec.2012.09.003","url":null,"abstract":"<div><p><span>Asthma is a complex disorder of the airways that is characterized by T helper type 2 (Th2) inflammation. The pleiotrophic cytokine TSLP<span> has emerged as an important player involved in orchestrating the inflammation seen in asthma and other atopic diseases. Early research elucidated the role of TSLP on CD4</span></span><sup>+</sup><span> T cells<span>, and recent work has revealed the impact of TSLP on multiple cell types. Furthermore, TSLP plays an important role in the sequential progression of atopic dermatitis to asthma, clarifying the key role of TSLP in the pathogenesis of asthma, a finding with therapeutic implications.</span></span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 3","pages":"Pages e83-e88"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31963991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 62
Modulation of asthma pathogenesis by nitric oxide pathways and therapeutic opportunities 通过一氧化氮途径和治疗机会调节哮喘发病机制
Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 DOI: 10.1016/j.ddmec.2012.10.004
Sudakshina Ghosh , Serpil C. Erzurum
{"title":"Modulation of asthma pathogenesis by nitric oxide pathways and therapeutic opportunities","authors":"Sudakshina Ghosh ,&nbsp;Serpil C. Erzurum","doi":"10.1016/j.ddmec.2012.10.004","DOIUrl":"10.1016/j.ddmec.2012.10.004","url":null,"abstract":"<div><p><span><span>Asthma, a chronic airway inflammatory disease is typically associated with high levels of exhaled </span>nitric oxide<span><span> (NO). Over the past decades, extensive research has revealed that NO participates in several metabolic pathways that contribute to animal models of asthma and human asthma. In asthmatic airway, high levels of NO lead to greater formation of </span>reactive nitrogen species (RNS), which modify proteins adversely affecting functional activities. By contrast, high levels of NO are associated with lower than normal levels of </span></span><em>S</em><span>-nitrosothiols, which serve a bronchodilator function in the airway. Detailed mechanistic studies have enabled the development of compounds that target NO metabolic pathways, and provide opportunities for novel asthma therapy. This review discusses the role of NO in asthma with the primary focus on therapeutic opportunities developed in recent years.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 3","pages":"Pages e89-e94"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31683964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Antiestrogen resistance and the application of systems biology 抗雌激素抵抗及其系统生物学的应用
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-01 DOI: 10.1016/j.ddmec.2012.10.003
Kerrie B Bouker , Yue Wang , Jianhua Xuan , Robert Clarke
{"title":"Antiestrogen resistance and the application of systems biology","authors":"Kerrie B Bouker ,&nbsp;Yue Wang ,&nbsp;Jianhua Xuan ,&nbsp;Robert Clarke","doi":"10.1016/j.ddmec.2012.10.003","DOIUrl":"10.1016/j.ddmec.2012.10.003","url":null,"abstract":"<div><p>Understanding the molecular changes that drive an acquired antiestrogen<span><span> resistance phenotype is of major clinical relevance. Previous methodologies for addressing this question have taken a single gene/pathway approach and the resulting gains have been limited in terms of their clinical impact. Recent systems biology approaches allow for the integration of data from high throughput ‘-omics’ technologies. We highlight recent advances in the field of antiestrogen resistance with a focus on transcriptomics, </span>proteomics and methylomics.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e11-e17"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40233339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Modulation of estrogen chemical carcinogenesis by botanical supplements used for postmenopausal women's health 经植物补充剂用于绝经后妇女健康的雌激素化学致癌调节
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-04 DOI: 10.1016/j.ddmec.2012.11.001
Courtney S. Snelten, Birgit Dietz, Judy L. Bolton
{"title":"Modulation of estrogen chemical carcinogenesis by botanical supplements used for postmenopausal women's health","authors":"Courtney S. Snelten,&nbsp;Birgit Dietz,&nbsp;Judy L. Bolton","doi":"10.1016/j.ddmec.2012.11.001","DOIUrl":"10.1016/j.ddmec.2012.11.001","url":null,"abstract":"<div><p><span>Breast cancer risk has been associated with long-term estrogen exposure including traditional hormone therapy<span><span> (HT, formally hormone replacement therapy). To avoid traditional HT and associated risks, women have been turning to botanical supplements such as black cohosh, red clover, </span>licorice<span><span>, hops, dong gui, and ginger to relieve menopausal symptoms despite a lack of efficacy evidence. The mechanisms of estrogen carcinogenesis involve both hormonal and chemical pathways. Botanical supplements could protect women from estrogen carcinogenesis by modulating key enzymatic steps [aromatase, CYP1B1, </span>CYP1A1, catechol-</span></span></span><em>O</em><span><span>-methyltransferase (COMT), NAD(P)H quinone oxidoreductase 1 (NQO1)] and reactive oxygen species<span><span> (ROS) scavenging in estradiol<span> metabolism leading to estrogen carcinogenesis. This review summarizes the influence of popular botanical supplements used for women's health on these key steps in the estrogen </span></span>chemical carcinogenesis pathway, and suggests that botanical supplements may have added chemopreventive benefits by modulating </span></span>estrogen metabolism.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e47-e54"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31858301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Targeting the genotoxic effects of estrogens 针对雌激素的基因毒性效应
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-13 DOI: 10.1016/j.ddmec.2012.11.005
Monica M. Montano, Nirmala Krishnamurthy, Smitha Sripathy
{"title":"Targeting the genotoxic effects of estrogens","authors":"Monica M. Montano,&nbsp;Nirmala Krishnamurthy,&nbsp;Smitha Sripathy","doi":"10.1016/j.ddmec.2012.11.005","DOIUrl":"10.1016/j.ddmec.2012.11.005","url":null,"abstract":"<div><p><span><span>Our studies indicate that expression of antioxidative stress enzymes is upregulated by Selective </span>Estrogen Receptor<span><span> Modulators (SERMs) in breast epithelial cell lines, providing protection against the genotoxic effects of estrogens and against estrogen-induced mammary tumorigenesis. This upregulation of antioxidative stress enzymes requires Estrogen Receptor beta (ERβ) and human homolog of </span>Xenopus gene which Prevents </span></span>Mitotic Catastrophe<span> (hPMC2). Further studies indicate that hPMC2 has a functional exonuclease domain that is required for upregulation of antioxidative stress enzymes by SERMs and repair of estrogen-induced abasic sites.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e29-e33"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31528419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose, duration and mode of administration of hormones influence breast cancer risk 激素的剂量、持续时间和使用方式影响乳腺癌的风险
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2013-01-17 DOI: 10.1016/j.ddmec.2012.10.001
Lakshmanaswamy Rajkumar
{"title":"Dose, duration and mode of administration of hormones influence breast cancer risk","authors":"Lakshmanaswamy Rajkumar","doi":"10.1016/j.ddmec.2012.10.001","DOIUrl":"10.1016/j.ddmec.2012.10.001","url":null,"abstract":"<div><p>Majority of breast cancers are diagnosed in post-menopausal women. Hormone replacement therapy has been indicated as one of the major causes of increasing breast cancer risk in these women. Several epidemiological studies have attempted to discover the association between hormone replacement therapy and breast cancer. Because of the nature of data collection and study design it has been difficult to assess the real effect of hormone replacement therapy on breast cancer risk. Several hormones are biphasic in nature and one needs to take into account that the dose, duration and mode of administration of hormones could have a significant impact on increasing or decreasing the risk of breast cancer. This review will attempt to provide a broad summary of the evidence to date on the breast cancer risk associated with dose, duration and mode of administration of hormone replacement therapies.</p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e5-e9"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74420225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The etiology and prevention of breast cancer 癌症的病因及预防。
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2013-03-07 DOI: 10.1016/j.ddmec.2013.02.001
Ercole L. Cavalieri , Eleanor G. Rogan
{"title":"The etiology and prevention of breast cancer","authors":"Ercole L. Cavalieri ,&nbsp;Eleanor G. Rogan","doi":"10.1016/j.ddmec.2013.02.001","DOIUrl":"10.1016/j.ddmec.2013.02.001","url":null,"abstract":"<div><p><span><span>Metabolism of estrogens via the catechol estrogen<span><span> pathway is characterized by a balanced set of activating and protective enzymes (homeostasis). Disruption of </span>homeostasis, with excessive production of catechol estrogen </span></span>quinones<span>, can lead to reaction of these quinones with DNA<span><span> to form depurinating estrogen-DNA adducts. Some of the mutations generated by these events can lead to initiation of breast cancer. A wealth of evidence, from studies of metabolism, mutagenicity, cell transformation and </span>carcinogenicity, demonstrates that estrogens are genotoxic. Women at high risk for breast cancer, or diagnosed with the disease, have relatively high levels of depurinating estrogen-DNA adducts compared to normal-risk women. The dietary supplements </span></span></span><em>N</em><span>-acetylcysteine and resveratrol can inhibit formation of catechol estrogen quinones and their reaction with DNA to form estrogen-DNA adducts, thereby preventing initiation of breast cancer.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e55-e69"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2013.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34070133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
The role of androgen receptor in breast cancer 雄激素受体在乳腺癌中的作用。
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-07 DOI: 10.1016/j.ddmec.2012.11.003
Domenico Iacopetta , Yassine Rechoum , Suzanne A.W. Fuqua
{"title":"The role of androgen receptor in breast cancer","authors":"Domenico Iacopetta ,&nbsp;Yassine Rechoum ,&nbsp;Suzanne A.W. Fuqua","doi":"10.1016/j.ddmec.2012.11.003","DOIUrl":"10.1016/j.ddmec.2012.11.003","url":null,"abstract":"<div><p><span>The androgen receptor (AR) is a proven clinical target in </span>prostate cancer<span>. Recent research indicates that it is an emerging hormonal target in breast cancer as well, with potential clinical benefit in both estrogen receptor<span> (ER) positive and negative tumors. Compared to the ER, AR contains unique functional domains with relevance to its altered role in human breast cancer. The majority of ER-positive tumors express AR, and a significant percentage of ER-negative tumors might benefit from combined targeting of AR and the ErbB2/HER2 oncogene. Signaling downstream of AR might also affect many clinically important pathways which are also emerging clinical targets in breast cancer. AR expression might also play a role during tumor progression to metastatic disease. The role of AR as a new important biomarker in breast cancer will be reviewed herein.</span></span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e19-e27"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82798213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 50
Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer 儿茶酚- o -甲基转移酶:特征、多态性及其在乳腺癌中的作用
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-01 DOI: 10.1016/j.ddmec.2012.10.002
James D. Yager
{"title":"Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer","authors":"James D. Yager","doi":"10.1016/j.ddmec.2012.10.002","DOIUrl":"10.1016/j.ddmec.2012.10.002","url":null,"abstract":"<div><p><span><span><span>Catechol estrogens are carcinogenic, probably because of their estrogenicity and potential for further </span>oxidative metabolism to reactive </span>quinones<span>. Estrogenic quinones cause oxidative DNA damage as well as form mutagenic depurinating adenine<span> and guanine adducts. </span></span></span><em>O</em>-Methylation by catechol-<em>O</em><span>-methyltransferase (COMT) blocks their estrogenicity and prevents their oxidation<span> to quinones. A single gene encodes both membrane bound (MB) and soluble (S) forms of COMT. The COMT gene contains 34 single nucleotide polymorphisms (SNPs). The valine108 (S-COMT)/158 (MB-COMT) SNP encodes a low activity form of COMT and has been widely studied as a putative risk factor for breast cancer, with inconsistent results. Investigations of two other SNPs in the promoter of MB-COMT that may affect its expression have also provided mixed results. Future studies on the role of COMT in breast cancer should incorporate measurement of biomarkers that reflect COMT activity and its protective effects.</span></span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e41-e46"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31478707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 42
An in vitro–in vivo model of epithelial mesenchymal transition in triple negative breast cancer 三阴性乳腺癌上皮间充质转化的体内外模型
Drug discovery today. Disease mechanisms Pub Date : 2012-06-01 Epub Date: 2012-12-05 DOI: 10.1016/j.ddmec.2012.11.002
Yubo Zhai, Julia Santucci-Pereira, Ricardo Lopez de Cicco, Irma H. Russo, Jose Russo
{"title":"An in vitro–in vivo model of epithelial mesenchymal transition in triple negative breast cancer","authors":"Yubo Zhai,&nbsp;Julia Santucci-Pereira,&nbsp;Ricardo Lopez de Cicco,&nbsp;Irma H. Russo,&nbsp;Jose Russo","doi":"10.1016/j.ddmec.2012.11.002","DOIUrl":"10.1016/j.ddmec.2012.11.002","url":null,"abstract":"<div><p><span>The loss of epithelial expression markers by neoplastic breast cancer cells in the primary tumor is believed to play a pivotal role during breast cancer metastasis. This phenomenon is the hallmark of the epithelial mesenchymal transition<span> (EMT) process. Gene expression microarrays were performed to investigate key functional elements on an </span></span><em>in vitro</em><span> metastasis model derived from human breast epithelial cells (MCF10F) treated with 17 beta estradiol. We identified groups of SLUG associated genes modulated during EMT.</span></p></div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"9 1","pages":"Pages e35-e40"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2012.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31449823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书